Antibiotics Poised For ‘Breakthrough’-Style Changes At FDA, Venture Capitalist Say
This article was originally published in The Pink Sheet Daily
Executive Summary
Even if FDA already has authorities, legislation can energize agency, Third Rock Ventures’ Borisy tells Senate, adding limited population approval should be extended beyond antibiotics to other disease areas.